Payment overview · 2025
General Payments
$714.11
41 reported records · 20 companies
Healthcare provider profile · identity verified
Christopher J Godfrey, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ELIZABETHTOWN, KY · NPI 1679564439
Verified facts
What the public records show
CMS Open Payments records show Christopher J Godfrey, MD received $714.11 in general payments during 2025 across 41 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 26.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Qulipta, Rexulti, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rytary by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1076 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $190.45 | 26.7% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $136.93 | 19.2% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.53 | 4.8% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $34.43 | 4.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.94 | 4.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.80 | 4.2% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $26.43 | 3.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.64 | 3.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.28 | 3.1% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $21.50 | 3.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.23 | 3.0% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $20.49 | 2.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.06 | 2.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.24 | 2.4% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $15.90 | 2.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.15 | 2.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.69 | 2.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $14.52 | 2.0% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $14.26 | 2.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.64 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $714.11 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $190.45 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $97.32 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $76.57 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.61 | 4 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $34.43 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.94 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.80 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $26.43 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 130 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 130 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
182 | 46 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
130 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
202 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
100 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
189 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
130 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1076 | 138 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
36 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1526 | 318 |
| Eliquis | Apixaban | 1076 | 138 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1038 | 259 |
| Metoprolol Succinate | Metoprolol Succinate | 992 | 230 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 932 | 256 |
| Furosemide | Furosemide | 870 | 181 |
| Pantoprazole Sodium | Pantoprazole Sodium | 870 | 223 |
| Amlodipine Besylate | Amlodipine Besylate | 860 | 224 |
| Potassium Chloride | Potassium Chloride | 785 | 176 |
| Gabapentin | Gabapentin | 689 | 138 |
| Lisinopril | Lisinopril | 560 | 139 |
| Lorazepam | Lorazepam | 531 | 94 |
| Duloxetine Hcl | Duloxetine Hcl | 527 | 99 |
| Losartan Potassium | Losartan Potassium | 521 | 130 |
| Carvedilol | Carvedilol | 503 | 110 |
| Sertraline Hcl | Sertraline Hcl | 493 | 103 |
| Omeprazole | Omeprazole | 489 | 121 |
| Tamsulosin Hcl | Tamsulosin Hcl | 459 | 107 |
| Metformin Hcl | Metformin Hcl | 448 | 116 |
| Famotidine | Famotidine | 432 | 111 |
| Trazodone Hcl | Trazodone Hcl | 376 | 77 |
| Montelukast Sodium | Montelukast Sodium | 328 | 98 |
| Memantine Hcl | Memantine Hcl | 320 | 51 |
| Temazepam | Temazepam | 312 | 48 |
| Donepezil Hcl | Donepezil Hcl | 310 | 70 |
| Quetiapine Fumarate | Quetiapine Fumarate | 306 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 282 | 66 |
| Mirtazapine | Mirtazapine | 274 | 63 |
| Valsartan | Valsartan | 273 | 66 |
| Clopidogrel | Clopidogrel Bisulfate | 268 | 56 |
| Spironolactone | Spironolactone | 251 | 66 |
| Citalopram Hbr | Citalopram Hydrobromide | 231 | 56 |
| Zolpidem Tartrate | Zolpidem Tartrate | 228 | 28 |
| Clonazepam | Clonazepam | 224 | 39 |
| Simvastatin | Simvastatin | 223 | 56 |
| Tramadol Hcl | Tramadol Hcl | 223 | 45 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 211 | 44 |
| Meloxicam | Meloxicam | 210 | 47 |
| Prednisone | Prednisone | 207 | 112 |
| Jardiance | Empagliflozin | 202 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 201 | 57 |
| Trulicity | Dulaglutide | 189 | 32 |
| Synthroid | Levothyroxine Sodium | 182 | 46 |
| Warfarin Sodium | Warfarin Sodium | 182 | 35 |
| Allopurinol | Allopurinol | 177 | 45 |
| Januvia | Sitagliptin Phosphate | 173 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 169 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 168 | 70 |
| Levetiracetam | Levetiracetam | 167 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 166 | 61 |
| Hydralazine Hcl | Hydralazine Hcl | 165 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 51 |
| Glipizide | Glipizide | 162 | 36 |
| Azithromycin | Azithromycin | 159 | 102 |
| Ropinirole Hcl | Ropinirole Hcl | 157 | 36 |
| Nystatin | Nystatin | 155 | 62 |
| Bupropion Xl | Bupropion Hcl | 153 | 40 |
| Alprazolam | Alprazolam | 146 | 22 |
| Metformin Hcl Er | Metformin Hcl | 145 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 144 | 48 |
| Baclofen | Baclofen | 142 | 33 |
| Celecoxib | Celecoxib | 141 | 30 |
| Cephalexin | Cephalexin | 139 | 67 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 139 | 36 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 138 | 39 |
| Doxycycline Hyclate | Doxycycline Hyclate | 137 | 80 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 134 | 41 |
| Lactulose | Lactulose | 132 | 17 |
| Torsemide | Torsemide | 131 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 130 | 32 |
| Ozempic | Semaglutide | 130 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 130 | 23 |
| Finasteride | Finasteride | 129 | 31 |
| Ondansetron Hcl | Ondansetron Hcl | 129 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 64 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 125 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 121 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 118 | 53 |
| Ondansetron Odt | Ondansetron | 116 | 50 |
| Pregabalin | Pregabalin | 116 | 30 |
| Levofloxacin | Levofloxacin | 115 | 88 |
| Buspirone Hcl | Buspirone Hcl | 114 | 32 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 112 | 34 |
| Clonidine Hcl | Clonidine Hcl | 109 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 104 | 26 |
| Xarelto | Rivaroxaban | 102 | 11 |
| Benazepril Hcl | Benazepril Hcl | 100 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 100 | 30 |
| Mounjaro | Tirzepatide | 100 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 99 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 26 |
| Levemir | Insulin Detemir | 95 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 93 | 25 |
| Lamotrigine | Lamotrigine | 91 | 13 |
| Divalproex Sodium | Divalproex Sodium | 90 | 18 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 88 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 86 | suppressed |
| Fluconazole | Fluconazole | 83 | 52 |
| Ezetimibe | Ezetimibe | 82 | 26 |
| Atenolol | Atenolol | 81 | 25 |
| Meclizine Hcl | Meclizine Hcl | 78 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 77 | 19 |
| Propranolol Hcl | Propranolol Hcl | 77 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 76 | 23 |
| Budesonide | Budesonide | 75 | 14 |
| Dexamethasone | Dexamethasone | 75 | 64 |
| Irbesartan | Irbesartan | 74 | 19 |
| Sucralfate | Sucralfate | 74 | 19 |
| Ibuprofen | Ibuprofen | 72 | 32 |
| Digoxin | Digoxin | 70 | 17 |
| Risperidone | Risperidone | 70 | 11 |
| Midodrine Hcl | Midodrine Hcl | 68 | 24 |
| Myrbetriq | Mirabegron | 68 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 67 | 21 |
| Bumetanide | Bumetanide | 66 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | 19 |
| Levemir Flexpen | Insulin Detemir | 64 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 63 | 42 |
| Paroxetine Hcl | Paroxetine Hcl | 61 | 17 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 61 | suppressed |
| Topiramate | Topiramate | 61 | 11 |
| Cefdinir | Cefdinir | 60 | 46 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 38 |
| Colestipol Hcl | Colestipol Hcl | 57 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 56 | suppressed |
| Nifedipine Er | Nifedipine | 56 | 12 |
| Fenofibrate | Fenofibrate | 55 | suppressed |
| Lansoprazole | Lansoprazole | 55 | 14 |
| Estradiol | Estradiol | 54 | 21 |
| Methylprednisolone | Methylprednisolone | 54 | 49 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 54 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 40 |
| Glimepiride | Glimepiride | 52 | 13 |
| Alendronate Sodium | Alendronate Sodium | 50 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 50 | 19 |
| Ipratropium Bromide | Ipratropium Bromide | 50 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 48 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 47 | 18 |
| Brimonidine Tartrate | Brimonidine Tartrate | 46 | suppressed |
| Aripiprazole | Aripiprazole | 45 | suppressed |
| Loperamide | Loperamide Hcl | 43 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 43 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | 11 |
| Colchicine | Colchicine | 41 | 19 |
| Valacyclovir | Valacyclovir Hcl | 41 | 25 |
| Methotrexate | Methotrexate Sodium | 40 | suppressed |
| Novolog | Insulin Aspart | 40 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 39 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 39 | 15 |
| Hydrocortisone | Hydrocortisone | 37 | 16 |
| Metolazone | Metolazone | 37 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 36 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 36 | 13 |
| Mupirocin | Mupirocin | 36 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 36 | 12 |
| Diazepam | Diazepam | 35 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 35 | 17 |
| Humalog | Insulin Lispro | 34 | suppressed |
| Jantoven | Warfarin Sodium | 34 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Naproxen | Naproxen | 33 | 14 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 33 | suppressed |
| Klayesta | Nystatin | 32 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 32 | suppressed |
| Xifaxan | Rifaximin | 31 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | 11 |
| Candesartan Cilexetil | Candesartan Cilexetil | 30 | suppressed |
| Lidocaine | Lidocaine | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Rytary | Carbidopa/Levodopa | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Qulipta | Atogepant | 28 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 27 | 17 |
| Linzess | Linaclotide | 27 | 11 |
| Megestrol Acetate | Megestrol Acetate | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | 11 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | 16 |
| Latanoprost | Latanoprost | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 15 |
| Nitroglycerin Patch | Nitroglycerin | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 24 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 24 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 11 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 24 | suppressed |
| Rexulti | Brexpiprazole | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Timolol Maleate | Timolol Maleate | 23 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Insulin Aspart | Insulin Aspart | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Erythromycin | Erythromycin Base | 20 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Constulose | Lactulose | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Insulin Lispro | Insulin Lispro | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | 13 |
| Ketoconazole | Ketoconazole | 19 | 11 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 18 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 18 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 16 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 16 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Etodolac | Etodolac | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 13 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 12 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Minivelle | Estradiol | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Glucagon Emergency Kit | Glucagon | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Timolol Maleate | Timolol Maleate/Pf | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $714.11 · 41 records | Otsuka America Pharmaceutical, Inc. | Auvelity, CAPLYTA, Cologuard Collection Kit, FREESTYLE LIBRE 3, INJECTAFER, KISUNLA, Kerendia, LOREEV XR, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, QUTENZA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TZIELD, UBRELVY, UNITHROID, VRAYLAR, Veozah, WATCHMAN Access System, Wegovy, XYOSTED, ZAVZPRET | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error